



An update on Avacopan Vifor (avacopan) in the UK

This communication is intended for UK Healthcare Professionals and UK Decision Makers.

Dear ANCA-associated vasculitis community,

We wanted to inform you that the Medicines and Healthcare products Regulatory Agency (MHRA) have informed CSL of the following:

- The MHRA has decided to suspend the use, sale, supply and offer for sale or supply of Avacopan Vifor in the UK from **1 September 2026**. This is because the licensing authority considers that the positive therapeutic effects of the product do not outweigh the risks of the product to the health of patients or of the public.
- Existing patients may continue treatment during a six-month transitional period ending on **1 March 2027**. The purpose of the limited supply is to minimise disruption to patient care and allow treating clinicians to transition those patients safely to alternative treatments.
- The MHRA has indicated its intention to revoke the licence on **1 March 2027**
- **No new patients may be supplied with Avacopan Vifor.**

While we are disappointed by the decision, we respect the outcome of the regulatory process and are committed to implementing it in full.

What happens now?

Clinicians should discuss individual treatment plans with patients currently receiving Avacopan Vifor to ensure transition to other medicines based on clinical need.

How are we supporting the community?

We want to reassure you that VFMCRP and CSL remain committed to the wider ANCA associated vasculitis (AAV) community in the UK and globally. Patient care remains our highest priority. We are working closely with health authorities to provide clear information to patient communities and healthcare professionals (HCPs) on next steps. Our teams and medical information services are focused on supporting patient communities and HCPs through this transition.

For more information

For further information about this update, please reach out to CSL Medical Information medicalinfo_UK@viforpharma.com.

Sincerely,

Marie Li
Head of Medical Affairs UK and Ireland
CSL (CSL is, with Fresenius Medical Care, a joint venture member of VFMCRP)

**About ANCA-associated vasculitis (GPA/MPA)**

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a life-threatening disease where the body's immune system mistakenly attacks its own blood vessels. This causes inflammation and irreversible organ damage, most frequently to the kidneys, and lungs, and requires treatment to manage the disease. The two main forms are granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Both disease and treatment burden markedly diminish quality of life for affected patients. ANCA-associated vasculitis can have a significant impact on patients' health and quality of life and requires specialist medical management.

Adverse events should be reported.

Reporting forms and information for the United Kingdom can be found at <https://yellowcard.mhra.gov.uk/> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Vifor Pharma Ltd.

Tel +44 1276 853633. Email: MedicalInfo_UK@viforpharma.com